For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Calithera Biosciences CX-839-014
A Phase 2 Randomized, Multicenter, Double-Blind Study Of The Glutaminase Inhibitor Telaglenastat With Pembrolizumab And Chemotherapy Versus Placebo With Pembrolizumab And Chemotherapy In First-Line, Metastatic KEAP1/NRF2-Mutated, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC)
To determine the amount of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against your type of cancer than the standard drugs alone.
DiagnosisPatients have non-small cell lung cancer (NSCLC) that has spread to other areas of the body (metastatic) and have not yet been treated for metastatic disease.
Non-Squamous, Non-Small Cell Lung Cancer
1st line, KEAP1 or NRF2 mutation, ECOG 0-1
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Patients will be randomly assigned to take either telaglenastat or placebo plus the standard cancer drugs.
Patients will be included in the safety evaluation period to determine what is the appropriate amount of telaglenastat to give in combination with pembrolizumab, carboplatin, and pemetrexed.
For more information, visit ClinicalTrials.gov